Embedded Files
GLP-1 10-year market outlook..pdfGLP-1 Market Forecast: Eli Lilly vs Novo Nordisk
GLP-1 Market Forecast: Eli Lilly vs Novo Nordisk
A forward-looking GLP-1 forecast connecting clinical science, regulatory context, and market access to real-world value.
Bayesian Methods in Clinical Trials FDA Guidance and the Future of Drug Development.pdfBayesian Methods in Clinical Trials
Bayesian Methods in Clinical Trials
A modern, probability-driven approach connecting FDA guidance, evolving trial design, and ethically sound go/no-go decisions.
FrontMIND phase 3 trial insights.pdffrontMIND Phase III clinical trial results
frontMIND Phase III clinical trial results
A concise visual narrative of the frontMIND Phase III trial, highlighting study design, primary outcomes, and key takeaways.
Top 5 picks of 2025.pdfTop 5 FDA-Approved Therapies of 2025
Top 5 FDA-Approved Therapies of 2025
A snapshot-style visual overview of five notable FDA approvals in 2025, summarizing mechanism of action, pivotal trial outcomes, and why each therapy matters in the current clinical landscape.
Tracing oral wegovy's path to approval.pdfTracing Oral Wegovy’s Path to Approval
Tracing Oral Wegovy’s Path to Approval
A visual narrative mapping the clinical and regulatory journey of oral semaglutide- from Phase III OASIS 4 data to FDA approval- clarifying trial design, outcomes, and regulatory milestones.
Orforglipron met the primary endpoint, showing superior maintenance of body weight reduction compared to placebo in participants who had reached a weight plateau..pdfOrforglipron: ATTAIN-MAINTAIN Phase III Snapshot
Orforglipron: ATTAIN-MAINTAIN Phase III Snapshot
A concise visual summary of the ATTAIN-MAINTAIN Phase III trial, highlighting study design, efficacy outcomes, safety profile, and the clinical relevance of oral GLP-1 therapy for long-term weight maintenance.
Insights from TRIUMPH-4 .pdfKey Insights from TRIUMPH-4
A structured infographic summarizing efficacy, symptom improvement, cardiometabolic effects, and safety findings from the TRIUMPH-4 study
Key Insights from BREAKWATER Cohort 3
A structured infographic highlighting consistent efficacy of encorafenib + cetuximab across chemotherapy backbones, demonstrating preserved targeted benefit with both mFOLFOX6 and FOLFIRI in first-line BRAF V600E–mutant metastatic colorectal cancer.
Key Insights from NCCN 2026 - From Chemotherapy to ADCs
A structured infographic summarizing efficacy, sequencing logic, tolerability, and guideline implications of antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer- highlighting major first-line PFS gains, the move toward earlier ADC use (ADC-IO), and what this means for treatment sequencing and real-world practice.
Page updated
Google Sites
Report abuse